Digipath Files Patent Application for Test to Distinguish Hemp from Drug-type Cannabis
09 Avril 2019 - 3:15PM
InvestorsHub Cannabis NewsWire
Digipath Files Patent
Application for Test to Distinguish Hemp from Drug-type
Cannabis
Addresses Recent Request For
Proposal Issued by
DEA
LAS VEGAS, NV
-- April 9, 2019 -- Investorshub NewsWire
-- Digipath, Inc. (OTCQB: DIGP), a service-oriented independent testing laboratory, data
and media firm focused on the developing cannabis and hemp
markets, is pleased to announce
that in collaboration with VSSL of
Kelowna, BC, has filed a
provisional patent
application for a Field Testing Kit that can quickly determine
whether a plant sample is actually hemp, drug-type THC or drug-type
CBD.
Currently the only recourse for
law enforcement to make a determination of what is being
transported across state lines is lab based analytical testing of
the mature plants for their THC content to come in under the 0.3%
THC level. The Digipath-VSSL simple genetic field test will
allow for a DNA-based assay to clearly designate if plant material
at any stage of growth is industrial hemp or drug-type CBD and NOT
drug-type THC. Inability to determine what a sample is, and if it
is in compliance with prevailing law, has been an enormous problem
for law enforcement, hemp farmers, and others looking to ensure
full compliance. A recent High Times article details this problem, noting an instance where a
fully-compliant hemp shipment was wrongfully seized due to a
failure to properly identify the
cargo.
As one of the premier testing laboratories in
the United States, Digipath is looking to expand on its
services with a mobile product to serve the market need for a test
to distinguish the two cannabis strains. The patent application
filing comes following a recent Request for Proposal for “Hemp/Marijuana Field Test
Kits” posted by the United States Drug
Enforcement Agency. The request reads as
follows:
“The field test kit must
provide specificity to distinguish between hemp and marijuana. It
must be portable and rugged enough to be used in non-laboratory
environments or ambient conditions. All products shall be the most
current and up-to-date model/revision(s) available at the time of
delivery. Anticipated maximum quantities to be purchased will be
based on evaluation results and agency
need.”
.
“VSSL’s Chief
Scientist, Philippe Henry PhD and I, are very pleased to present an
immediate solution to an industry need that parallels the stated
Federal and State dilemma of proper genetic identification of
interstate transported cannabis,” stated Cindy Orser, PhD, Chief
Science Officer, Digipath. “The need was abundantly clear to us and
we were intent on providing a solution to this dilemma even before
the government’s request was posted. Moreover, the Request for
Proposal appears to call for exactly what we believe our technology
provides.”
“This new
“Field Test” is essentially, a cross between 23 and Me and a
paternity test for plants,” stated Todd Denkin, CEO, Digipath.
“Within minutes, our test can determine the nature of the plant
sample and which drug-type it belongs to. We believe there is a
significant market for this product, and the DEA’s recognition of
this need supports our pursuit of this
opportunity.”
About Digipath, Inc. & Digipath Labs,
Inc.
Digipath,
Inc. supports the
cannabis industry's best practices for reliable testing, data
acquisition, cannabis education and training, and brings unbiased
cannabis news coverage to the cannabis
industry. Digipath
Labs provides
pharmaceutical-grade analysis and testing to the cannabis industry
to ensure producers, consumers, and patients know exactly what is
in the cannabis they ingest and to help maximize the quality of its
client's products through analysis, research, development, and
standardization.
Digipath Investor Relations & Financial
Media
Integrity Investor
Relations
info@integrityir.com
Toll Free: (888) 216-3595
www.IntegrityIR.com
Information
about Forward-Looking Statements
This press release
contains "forward-looking statements" that include information
relating to future events. Forward-looking statements should not be
read as a guarantee of future performance or results and will not
necessarily be accurate indications of the times at, or by, which
that performance or those results will be achieved. Forward-looking
statements are based on information available at the time they are
made and/or management's good faith belief as of that time with
respect to future events and are subject to risks and uncertainties
that could cause actual performance or results to differ materially
from those expressed in, or suggested by, the forward-looking
statements. Important factors that could cause these differences
include, but are not limited to: the Company's need for additional
funding, the demand for the Company's products, governmental
regulation of the cannabis industry, the Company's ability to
maintain customer and strategic business relationships, the impact
of competitive products and pricing, growth in targeted markets,
the adequacy of the Company's liquidity and financial strength to
support its growth, and other risks that may be detailed from
time-to-time in the Company's filings with the United States
Securities and Exchange Commission. For a more detailed description
of the risk factors and uncertainties affecting Digipath, please
refer to the Company's recent Securities and Exchange Commission
filings, which are available at www.sec.gov. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Digipath (PK) (USOTC:DIGP)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Digipath (PK) (USOTC:DIGP)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Digipath Inc (PK) (OTCMarkets): 0 recent articles
Plus d'articles sur Digipath (QB)